Enhancing plasticity of the central nervous system: Drugs, stem cell therapy and neuro-implants
Alice Le Frie, Anne-Sophie Salabert, Carole Davoust, Boris Demain, Christophe Vieu, Laurence Vaysse, Pierre Payoux, Isabelle Loubinoux

To cite this version:

HAL Id: hal-01629177
https://hal.laas.fr/hal-01629177
Submitted on 6 Nov 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Enhancing plasticity of the central nervous system: Drugs, stem cell therapy and neuro-implants.

Alice Le Friec\textsuperscript{1}, Anne-Sophie Salabert\textsuperscript{1,2}, Carole Davoust\textsuperscript{1}, Boris Demain\textsuperscript{1}, C Vieu\textsuperscript{3}, Laurence Vaysse\textsuperscript{1}, Pierre Payoux\textsuperscript{1,4}, I. Loubinoux\textsuperscript{1}.

\textsuperscript{1}ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France
\textsuperscript{2}Radiopharmacy Department, CHU Toulouse, France
\textsuperscript{3}LAAS-CNRS, Université de Toulouse, CNRS, INSA, UPS, Toulouse, France
\textsuperscript{4}Nuclear Medicine Department, CHU Toulouse, France

Corresponding author:
Isabelle Loubinoux
UMR1214 – Inserm/UPS – ToNIC
CHU PURPAN
Pavillon Baudot
Place du Dr Baylac
31024 Toulouse Cedex 3
France
Tel.: 33(5) 62 74 61 64
Fax: 33(5) 62 74 61 63
Email: isabelle.loubinoux@inserm.fr

Conflict of interest disclosure
The authors declare that there is no conflict of interest regarding the publication of this paper.
Abstract

Stroke represents the first cause of adult acquired disability. Spontaneous recovery, dependent on endogenous neurogenesis, allows for limited recovery in 50% of patients who remain functionally dependent despite physiotherapy. Here we propose a review of novel drug therapies with strong potential in the clinic. We will also discuss new avenues of stem cell therapy in patients with cerebral lesion. A promising future for the development of efficient drugs to enhance functional recovery after stroke seems evident. These drugs will have to prove efficacy also in severely affected patients. The efficacy of stem cell engraftment has been demonstrated, but will have to prove its potential in restoring tissue function for the massive brain lesions that are most debilitating. New answers may lay in biomaterials, a steadily growing field. Biomaterials should ideally resemble lesioned brain structures in architecture and must be proven to increase functional reconnections within host tissue before clinical testing.
Introduction

Pathologies such as stroke remain chronically debilitating despite scientific advances in the vast field of CNS injury. Following the acute phase, there are no effective treatments available to patients besides physiotherapy.

It is now well-known that various mechanisms of brain plasticity occur after stroke onset, both in the acute phase and beyond [1–6]. They may partially account for the spontaneous recovery of motor function [7]. Therefore, drug treatments have increasingly aimed to enhance these processes in order to improve functional recovery [8].

As for tissue repair of the lesioned area, endogenous neurogenesis does not however produce mature neuronal and glial cells in sufficient number to completely regenerate lesioned CNS tissue [9]. Over the last decades, this observation has led to intense focus on stem cell therapy for the treatment of acute and focal CNS damage produced by pathologies such as stroke, traumatic brain injury and spinal cord injury (SCI). Transplanted stem cells are expected to (i) exert trophic effects on host tissue by secretion of beneficial factors and/or (ii) actually replace lost tissue and establish functional short or long-distance connections with host cells. Numerous neural and non-neural stem cell types have shown promise in experimental rodent models of stroke [10, 11] and non-human primate (NHP) models of SCI [12]. This preclinical evidence has allowed stem cell delivery to be clinically tested for safety and efficacy in the treatment of stroke [13, 14], TBI [15, 16] and SCI [17]. However, stem cell trials for brain repair have yet to show consistent results respective to efficacy and functional improvement in Man [18].

Indeed, when considering stem cell graft within the lesion site, it is important to stress the inhospitable nature of the tissue. Excitotoxicity, inflammatory processes, glial scar formation, growth-inhibiting factors, abnormal tissue structure and loss of extracellular matrix
components render the lesion site unfavorable to neuroblast survival and differentiation [19, 20]. Stem cells grafted close to the brain lesion may die despite immunosuppressant therapy [21].

A promising way to provide endogenous neuroblasts and grafted cells with a suitable microenvironment may consist in the development of biomaterial ECM replacements and “scaffolds” [22]. Biomaterials aiming to mimic the ECM have enhanced tissue reconstruction in models of stroke [23]. They may also be engineered to deliver trophic factors [24] or to guide axonal growth [25]. Implantation of biomaterial has just reached first-in-Man clinical testing in the injured spinal cord [26].

Co-transplantation of biomaterial and stem cells has been successfully tested in preclinical studies for the treatment of stroke in the chronic phase in rodents [27, 28]. Although the translation of such therapies to the clinic presents technical challenges, we believe this technology opens up exciting avenues of treatment for focal chronic brain injury.

Here we propose to review the most recent innovative drug, stem-cell and bio-material based therapies for the treatment of CNS injuries such as those caused by stroke and SCI.

1. Drugs
   a. Drugs for axon repair

Central Nervous System axons, unlike those in the Peripheral Nervous system, were long thought to have lost their capacity for regeneration after section. This concept now seems outdated. Many recent studies have revealed the existence of proteins, such as NOGO, within the myelin sheath that are capable of inhibiting axonal growth, and prevent axonal regeneration after a lesion. Drugs targeting these inhibitory proteins, such as anti-NOGOs, have been successfully tested in rodents and primates. Steven Cramer and colleagues conducted a double-blinded placebo controlled pilot study of GSK249320, a monoclonal anti-
MAG (myelin-associated glycoprotein) antibody, in patients presenting a moderate walking disability after stroke (0.5 m/sec on average 5 days after stroke). The drug was administered 24h and 9 days after stroke onset, and was well tolerated at the three doses tested (1, 5 or 15 mg/kg, i.v). Only the 5 mg/kg (n=9) dose significantly improved walking speed against placebo (n=17) in a 112-day period, and recovery was particularly marked in the first 60 days [29]. This result suggests that dose and duration of treatment may be further optimized. Experimental testing in animals also showed that early administration within the first week may be more efficient [30]. Unfortunately, a recent large trial on 134 patients was interrupted for lack of efficacy despite the safety of the humanized monoclonal antibody (Cramer et al. Stroke 2017). However, anti-NOGO or other molecules may prove efficacy of this strategy in the future.

b. Growth factors
Growth factors such as G-CSF (Granulocyte Colony-Stimulating Factor), known to recruit hematopoietic stem cells, have been considered for use in stroke therapy based on the rationale that they possess such beneficial properties in the acute phase of stroke as the inhibition of glutamate secretion, reduction of inflammation, and anti-apoptotic and anti-edema effects, as well as pro-angiogenesis and neurogenesis properties in the chronic phase [31]. However, no functional improvement was evidenced in a cohort of 548 patients [32]. Similar results were found for other growth factors, such as bFGF (basic Fibroblast Growth Factor or Trafermin), known to increase neurite growth. When administered in the acute phase, bFGF caused systemic adverse effects and mortality. The phase II/III trial was interrupted at 286 patients [33]. Another neurotrophic factor, Brain-Derived Neurotrophic Factor, was shown to be toxic. Thus it is not currently feasible to consider the use of such growth factors for therapy after ischemic stroke.
c. Selective Serotonin Re-uptake Inhibitors (SSRI)

Our team in Toulouse has focused on NeuroImaging as a means to develop and adapt biomarker-based therapeutic strategies. We propose candidate biomarkers for (1) use in motor outcome prediction [34–36] and (2) as therapeutic agents with proven efficacy as evaluated by fMRI [37–43]. Recent work in our laboratory, which was confirmed by other teams, has demonstrated that the ipsilesional motor cortex M1 is a key structure of motor recovery, and is thus a suitable target for drug-, stem-cell, and non-invasive brain stimulation-based therapies. Functional activations in the primary sensorimotor cortex may be enhanced by the administration of monoaminergic drugs. Drug-induced hyperactivations have been positively correlated with motor improvement, even in unique doses of treatment. However, this result was elicited in small groups of moderately disabled stroke patients, and work must be extended to more severely affected patients, who respond modestly to interventions. Our group demonstrated, in a double-blind placebo controlled multicentric clinical trial of 118 patients, including heavily affected stroke patients, that fluoxetine (Prozac) treatment significantly improves motor recovery (Fugl-meyer scale and motor NIHSS) when compared to placebo. Functional improvement was observed, and a higher number of patients regained independence in the treatment group (mRS, modified Rankin Score) [44]. In a recent study with another SSRI, a similar result was found along with a 50% reduction in the 3-month National Institutes of Health Stroke Scale compared with the baseline scores. This was achieved in 57 patients in the citalopram and 39 patients in the placebo group (Oskouie NNR 2017). Recommendations for the design of clinical drug studies in stroke have been produced [45]. The Cochrane review reported that while SSRIs may improve patient independence, deficit, neurological status, as well as lessen anxiety and depression, inter-trial heterogeneity limits the drawing of meaningful conclusions. Larger clinical trials are needed to validate fluoxetine as stroke treatment before it can be prescribed routinely in the clinic [46], and must
confirm treatment efficacy as well as determine optimal dose and length of treatment. To this end, phase III trials have been launched in Australia (http://affinitytrial.org), Sweden (http://www.effects.se) and the United Kingdom (http://focustrial.org.uk) [47], and aim to include 6000 patients, 4176 of which have already been enrolled (Focus 3127, Affinity 334, Effect 715). IRSS induce only minor and well-known adverse effects, and are well tolerated in stroke patients. Although clinical evidence of efficacy is pending, the benefit to risk ratio seems for now in favor of SSRIs prescription after ischemic stroke.

When considering the mechanism of action of this antidepressant, it is useful to evoke the historic experiments that first evidenced concomitant firing of neurons in the raphe nucleus during movement, leading Jacobs & Fornal to propose motor facilitation as a primary function of the serotoninergic system [48]. It follows that the benefit of IRSS treatment may be further enhanced by physiotherapy. Furthermore, recent studies have described other biological effects of SSRI drugs such as anti-inflammatory properties through microglial repression and reduction of neutrophil infiltration [49, 50], increase in BDNF secretion [51], as well as enhancement of neurogenesis (see next chapter) and neural stem cell survival and differentiation [52, 53], even in aged brain lesioned rats [54]. In line with the neurogenic effect of SSRI, studies have shown that fluoxetine improves declarative memory and increases hippocampal volume in patients suffering from post-traumatic stress disorder [55, 56].

2. Stem cell engraftment

Neurogenesis, defined as the capacity of the brain to produce new neurons, has been evidenced in Man [57] in neurogenic brain regions, namely the dentate gyrus of the hippocampus and in the subventricular zone of the cortex. These niches produce stem cells and progenitor cells, that are capable of migrating to damaged cortical and/or subcortical brain areas and replacing lost neurons in patients after stroke [1, 9, 58, 59]. However, few
neuroblasts survive to reach full neuronal differentiation. Those that do often remain confined to the lesion border and are thus incapable of replacing extensive losses of neuronal tissue. Recent work has shown that as few as 0.2% of lost neurons are replaced [9].

Stem-cell based therapeutic strategies aim to support and/or stimulate endogenous neurogenesis by engraftment of stem cells, most often through intravenous or intracerebral delivery. One benefit of stem cell therapy may be the release of neuroprotective, trophic or immunomodulatory factors by grafted cells. These so-called trophic effects occur rapidly after engraftment and may stimulate endogenous neurogenesis, angiogenesis and neovascularization, as well as reduce apoptosis and inflammation [60]. However, for massive brain injury and severely affected patients, trophic effects will unlikely allow sufficient tissue regeneration. In these cases particularly, engraftment of stem cells with a view to not only provide trophic support, but to also replace damaged neurons and brain tissue could be considered.

The least invasive method of stem cell delivery remains intravenous. This procedure is carried out for the delivery of hematopoietic or mesenchymal stem cells. Clinical trials must meet stringent GMP (Good Manufacturing Practices) norms that regulate the quality and safety of cells for engraftment. These regulations dictate all aspects of cell origin, from the composition of cell culture mediums (which must avoid reliance on products of animal origin), to the cell banks from which the cells are selected, which must be genetically stable and homogenous, and regularly tested for identity, viability and sterility.

   a. Mesenchymal stem cells
      i. Intravenous delivery

Mesenchymal stem cells have the advantage of being relatively easy to isolate and amplify from readily accessible tissue samples. In particular, they may be extracted more easily from
fat tissue than from bone marrow. Allogenic stem cell transplantation is rendered possible by
the fact that these cells do not express the Major Histocompatibility Complex (MHC) antigen.
Mesenchymal stem cells can be differentiated into many cell types (chondrocytes, osteoblasts,
osteocytes, adipocytes, myocytes, tendinocytes…) and possess capacity for migration toward
damaged tissue in the brain [61]. Intravenous administration of adult mesenchymal stem cells
has proven safe thus far [62–64] and potentially efficient. A recent study found that
intravenous delivery of multipotent progenitor cells, although well tolerated, did not produce
significant improvement [65]. However, the number of patients included (n = 126, intent-to-
treat population) may not have provided sufficient statistical power to show modest effects.
Clinical trials to evaluate the efficacy of the approach are ongoing (Resstore trial, principal
investigator: Olivier Detante). It is likely that any beneficial properties will result from
trophic effects, which may reduce neuroinflammation in the acute phase, and support the
neovascularization within the damaged parenchyma.

ii. Intracerebral delivery
A recent phase I/2a american trial has demonstrated the safety of an intracerebral graft of
mesenchymal stem cells, genetically engineered to transiently express notch-1, a factor known
to drive neuronal differentiation [13]. 18 patients with ischemic brain damage (11 of whom
were women), of an average of 61 years old, and presenting a stable and chronic motor
deficit, received the graft between 6 and 20 months after injury and were followed for a year
(n=16). 2.5, 5 or 10 million SB263 cells produced by SanBio were injected into the peri-
infarct. Proof of concept research showed cell survival 1 month after transplantation in
cerebrolesioned animals [13]. One serious adverse event was declared (asymptomatic sub-
dural hematoma). NIHSS neurological scale, European stroke scale and Fugl-Meyer scale
results evidenced significant improvement of recovery in graft recipients. However, for
ethical reasons, this study was not controlled by a group of patients receiving a control surgical procedure.

b. Intraspinal graft of olfactory ensheathing stem cells

Autologous engraftment of olfactory ensheathing cells, harvested from the olfactory mucosa of 3 chronic medullar injury patients produced a quite spectacular improvement in American Spinal Injury Association class (A to B or C) scores in two patients, and more local enhancement of motricity and sensitivity in the third patient [17]. Though the mechanisms of action of these cells are far from elucidated, it has been suggested that these “support cells” may reduce glial scar formation, rendering the lesion site more permissive to axonal regeneration.

c. Intracerebral graft of neural stem cells

The main challenge in tissue regeneration therapies is not only the replacement of lost neurons, but also the establishment of functional reconnections. In this view, selecting a cell source is difficult.

In a first phase 2 randomized clinical trial led by Kondziolka et al, the feasibility of intracerebral stem cell engraftment in 14 stable stroke patients was demonstrated [66, 67]. Although successfully differentiated into neurons, the hNT2 (LBS-Neurons, Layton Bioscience) stem cell line they used originates from a teratocarcinoma and is no longer authorized for trial in Man due to its extremely abnormal caryotype. The study included a small (n=4) group of control patients, paired for physiotherapy. Six out of eleven PET scans evidenced an improvement of glucose intake at the implantation site (3 injections were performed: above, within and below the lesion site). Improvement of functional recovery was not significant in the treated group compared to controls. Four treated patients, who presented lesions in the non-dominant hemisphere, showed enhanced performance in the figure of Rey test. This suggests improved visuospatial skills and non-verbal memory [68].
A recent phase 1 first-in-man study used the CTX0E03 or ReN001 cell line (ReNeuron) derived from genetically modified embryonic stem cells originating from human fetal neuroepithelium [14]. In order to control the amplification of cells, they used c-mycERT AM technology to drive expression of an oestradiol receptor under tamoxifen (4-OHT) induction (added to culture medium). Cell division is arrested and differentiation into neuronal and glial lineages was induced by removal of tamoxifen and growth factors from the medium. It is important to note that the use of tamoxifen for the treatment of breast cancer in women could restart division of the transplanted cells. For this reason, women were excluded from the protocol. Eleven men presenting a moderate to severe disability were enrolled for perilesional grafting of 2, 5, 10 or 20 million cells 6 to 60 months after stroke onset. Patients did not receive any immunosuppressive therapy. Patients were followed for 2 years as part of this non-controlled trial. No immunological or adverse effects were attributed to the grafted cells. Modest improvements of different motor scales were observed (NIHSS, Barthel index, Ashworth Spasticity Scale for the arm and leg, and a quality of life and health status EuroQoL Five Dimensions questionnaire EQ-5D).

Although the setup of methodologies to control trials with groups of operated-upon but non-grafted patients poses for now unsurmountable technical and ethical difficulties, the true efficacy of stem cell based interventions cannot be fully validated without this condition and larger patient cohorts. Perilesional injection of cells into healthy tissue is often performed in order to optimize stem cell survival. The rapidly occurring trophic effects of this approach is now well established, however true functional replacement of lost cells remains to be solidly demonstrated although difficult to test in humans.

While regenerative medicine strategies aim to replace the lesioned neural tissue by intracerebral engraftment, the lesion site microenvironment is unconducive to progenitor survival and differentiation due to the destruction of extracellular matrix (ECM) components
which can be replaced or isolated by scar tissue [19, 69]. Effectiveness of therapy is limited as only 5% of grafted cells survive. An exciting solution to this problem may be produced by nanotechnology scaffolds.

3. Neuro-implants

Biomaterials may provide a suitable support for cells, replacing lost extracellular matrix. They may promote cell survival and differentiation, revascularisation and recolonisation of lesioned tissue by glia and endothelium cells from the host. More complex biomimetic materials may also guide axonal growth towards their biological targets, restoring effective and even long-distance connections between damaged and healthy tissues. Where stroke is concerned, research in this innovative field remains currently preclinical.

a. Injectable nanometric biomaterials

i. Nanofibers

Fibrous biomaterials of nanometric dimension were injected in scar tissue in a rat model of medullar lesion. They were composed of peptides that auto-assemble to form fibers and contain epitopes of laminin, an ECM component involved in processes such as cell adhesion. Axons of the descending corticospinal tract and those of the ascending sensory neurons that could not previously cross the fibrous glial scar were able to penetrate the biomaterial and cross the lesion. Importantly, motor recovery was significantly enhanced in treated animals [70]. A biodegradable and biocompatible block copolymer of Poly-lactic-co-glycolic acid and Poly-L-lysine improves functional recovery of rats and non-human primates after a partial and complete lateral hemisection of the thoracic spinal cord [71]. INSPIRE, a clinical trial is ongoing and the safety of this approach in man has been published in one case [26].
ii. Hydrogels

Polymer hydrogels are another candidate biomaterial for the support of grafted cells. For instance, polyglycolic acid (PGA) is often used as it is porous, biodegradable and entirely synthetic, meaning its exact composition can be easily controlled. Park and coll. included neural stem cells in a soluble hydrogel which then polymerizes within the lesion site [72]. They demonstrated convincing tissue reconstruction in a rodent model of ischemic stroke (middle cerebral artery occlusion (MCAo) which produces massive lesions. The biomaterial is conducive to neurite growth, and connections were evidenced between host and grafted cells. Vascularisation, reduction of the glial scar and of monocyte infiltration was also found. This type of approach has shown promising results for sensorimotor and cognitive recovery [73].

iii. Micrometric injectable biomaterials

- Microbeads

Easily injectable micrometric biomaterial beads have also been developed. When injected in a rat model of Parkinson disease, they improved motricity, decreased striatal lesion volume and reduced substantia nigra degeneration [74].

- Structured and guiding biomaterial implants

Our team has proposed a strategy for the long distance bridging of brain regions using biomaterials seeded with neural stem cells, called neuro-implants, in collaboration with LAAS-CNRS (Fig. 1). They are made with PDMS (polydimethylsiloxane), and micro-structured to guide axonal growth in predefined directions (Fig. 2). We have conducted a proof of concept study of the efficacy of neuro-implants compared to implants alone in a rat model of corticostriatal lesion impacting the corticospinal tract, which produces loss of forelimb strength and dexterity [75]. The implants did not increase reactive astrogliosis, scarring or inflammatory responses. They improved survival of grafted cells, their maturation
and partial tissue reconstruction within the lesion site around the implants. Reconstructed tissue around the neuro-implants was vascularized as assessed by the HMPAO radiotracer perfusion with SPECT imaging (Fig 3). In contrast, lesioned tissue without implants evolved in a cystic cavity (Fig 3, red arrows). The increase in number of surviving grafted cells may also have trophic effects on cerebral plasticity, such as growth factor and anti-inflammatory factor secretion [76].

**Fig 1**: Neuro-implant concept. Guiding scaffolds located in a lesion of the corticospinal tract may improve tissue reconstruction and appropriate direction of regenerated tracts.
Fig. 2: Representative horizontal brain section of the lesioned area under brightfield illumination from Implants Alone (A, Scale bar: 1 mm) and neuro-implants rats (B). The newly generated tissue was mostly located around the PDMS implants. B: Human neural stem cells were identified by a specific human marker hNCAM or hMTCO2, in combination with a marker (in green) of immature (Nestin) and mature (MAP2) neurons. Low magnification is provided on the left and higher magnifications on the right (scale bars: 100µm). Grafted cell neurites were aligned along the grooves of the implant.
Fig. 3: Measurement of cerebral blood flow by nanoSPECT Plus-CT Bioscan with [99mTc]-HMPAO. Fifteen minutes after intravenous injection of 50 MBq of [99mTc]-HMPAO in the tail vein of Sprague Dawley anesthetized rats, data were acquired during 7 min for SPECT (48 sec and 100 000 cps per projection, image size 276*276*164, 0.1 mm) and 1 min for CT (55 kVp, 500 msec, pitch 0.5, binning 1:4). Following the reconstruction, the CT images were spatially aligned to match the SPECT images. Processing of reconstructed images was performed with the in-house Sysiphe software [77]. Brain implants were identified on CT (blue arrows) and 3D volumes of interest (VOIs) were drawn on either side of the implants (colored rectangles) and symetric ROIs were drawn on the contralateral side as a control (not shown). Images of two rats 20 days after a corticostriatal lesion and 7 days after implantation of neuro-implants. A,E: CT-scan of brain implants (blue arrows). One implant was inserted in rat #1 brain and 5 implants in rat #2 brain. B,F: SPECT-CT with HMPAO radiotracer on the area of brain implant. C, G: SPECT-CT with HMPAO radiotracer on the area of brain damage (located behind the implantation zone). We observed major hypoperfusion (red arrow). The presence of implants limited hypoperfusion: for rat #1, -13% in B compared to -25% in C (ROI volume was 0.4 mm$^3$), for rat #2, -18% in F compared to -57% in G (ROI volume was 1.5 mm$^3$). H: sagittal view of rat #1. Coronal views B and C are located with grey and red lines. D, I: Rat brain perfused and extracted 3 months after the lesion showing the lesion area where neuro-implants were inserted (grey arrows) or not (red arrows).

Conclusion
In summary, effective drug therapies are gradually becoming available to improve functional recovery after stroke. However, these will unlikely allow spectacular gains in patients with severe brain damage. Many research teams currently strive to demonstrate the efficacy of stem cell transplantation, which has shown promise in many preclinical models of brain injury. Nonetheless, stem cells alone may not repair the most extensive and debilitating lesions. Much hope has arisen from the development of biomaterial scaffolds, a rapidly growing field of research. These would ideally resemble the architecture of the brain in structure [78], and be proven to allow adequate reconnections with host tissue if possible. If not, given the complexity of this approach, they must at least provide a very high benefit before they can be considered in a clinical setting.

Acknowledgement

We thank Carine Pestourie who carried out rat SPECT/CT experiments (Non-Invasive Exploration Service -US006/CREFRE Inserm/UPS/ENVT Toulouse-France). We thank Laurence Vaysse who managed cell culture and immunohistology. This work has been in part supported by a grant from the French National Agency for Research called “Investissements d’Avenir” no. ANR-11-LABEX-0018-01.
References:


